XPS™ sold to China

XVIVO Perfusion has sold an XPS™ to the second largest lung transplant clinic in China. The purpose is to start EVLP (Ex Vivo Lung Perfusion)-research at the CHINA-JAPAN FRIENDSHIP HOSPITAL in Beijing. 

China is currently the fastest growing lung transplant market in the world, with a 35 % increase in lung transplants in 2018 (403 lung transplants performed). Due to the increased need for lung transplantation the number of clinics authorized to perform lung transplants has increased from 20 clinics in 2016 to 37 clinics in 2018.

The lung transplant program lead by Professor JINGYU CHEN will head the EVLP program at the CHINA-JAPAN FRIENDSHIP HOSPITAL in Beijing. It is the second largest lung transplant clinic in China. They will investigate the effects of EVLP on Lung transplantation. The research intention is to evaluate EVLP in the clinical environment in China, which will add Chinese data to the existing EVLP data from North America and Europe. XVIVO Perfusion has initiated a registration process of the XPS™ with the NMPA, the Chinese regulatory authority. In partnership with XVIVO Perfusion´s Distributor in China (Shanghai Genext Medical Technology Co., Ltd), the company plan to scientifically support the Lung transplant clinic of CHINA- JAPAN FRIENDSHIP HOSPITAL in Beijing.

“We are very delighted that we delivered another XPS to a clinic in China. Considering the size of the population and the fast increase in the standard of living and healthcare, China is expected to become an important market for XVIVO in the near future”, says Magnus Nilsson, CEO of XVIVO Perfusion.

September 18, 2019

Gothenburg
Magnus Nilsson, CEO

XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on September 18, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags:

Subscribe

Documents & Links